News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

Recently published White Paper reveals ways clinical laboratories and pathology groups can take advantage of growing opportunities in the area of pharmacogenomics

Increased understanding of the genetic basis of an individual’s response to drugs, including how and how quickly a drug is metabolized (pharmacodynamics and pharmacokinetics), has created rich opportunities for the establishment and expansion of PgX services.

Expertise such as this that is beyond traditional lab medicine is crucial to the future success
of your laboratory.

Pharmacodynamics and pharmacokinetics have opened the door to a progressively personalized approach to drug prescription. By identifying drugs most likely to benefit a patient, assessing the likely dose response, potentially avoiding adverse reactions, and reducing unnecessary use of drugs, pharmacogenomics testing (PgX) has helped optimize treatment and reduce costs associated with complications or inappropriate utilization.

As research demonstrating the clinical utility and associated health economics benefits of PgX has grown—along with the soaring trend toward value-based healthcare—PgX services are now on the path to becoming the standard of care. This demand for PgX presents a tremendous opportunity for clinical laboratories, many of which have already over the last few years successfully launched PgX services, and enjoyed robust growth. (more…)

Recently published White Paper discusses the importance of clinical diagnostics laboratories having a capable system to handle molecular testing needs

The laboratory industry’s forward thinkers define molecular diagnostics and genetic testing as both the future of pathology and the #1 opportunity to add clinical value while earning appropriate reimbursement.

Personalized medicine and predictive medicine have become a reality. As molecular technology and personalized medicine increasingly becomes the default position for clinical diagnostics laboratories, these modalities place significant demands on laboratory information systems. Although hospitals and healthcare institutions often focus on an electronic medical records system that includes a laboratory information system (LIS), those LIS’s do not typically have the functionality needed to handle current molecular testing needs, or needs expected in the near future. is pleased to offer a recently published White Paper that discusses the trends in increasing use of genetic and molecular testing, the growth of big data in healthcare, and the challenges facing laboratories in handling the complexities of personalized medicine. (more…)

Revisiting the Clinical Pathology Lab’s Problem of Floaters and Other Contaminates

As automation transforms the manual work processes in the histopathology laboratory, “floaters” may become a thing of the past

Any histotechnologist and pathologist familiar with the manual work processes commonly in use in histopathology laboratories knows about “floaters.” These are the pesky artifacts that are a consequence of the common practice of manually processing tissue through the series of H&E linear baths required for the proper staining of these samples prior to analysis by anatomic pathologists.

“Floaters” are a relevant example of why manual work processes in the histopathology laboratory can be the source of errors and mistakes. Certain types of floaters—including floaters consisting of malignant tissue fragments—have the potential to contaminate the patient specimen. This can negatively impact patient safety and even contribute to a misdiagnosis of the patient. Moreover, the issue of floaters has been around for decades, because the manual work processes involving the H&E (hematoxylin and eosin stain) linear baths have remained relatively unchanged during this time.


Threat to Clinical Pathology Laboratories is Payer Pre-Authorization of Genetic Tests

Health insurers want to control the rapid growth in expensive genetic and molecular assays

For many clinical laboratories and pathology groups, genetic tests and molecular diagnostic assays are the fastest-growing part of the test menu. This is true both in the increased volume of specimens for genetic tests and the growing number of such medical laboratory tests that are accepted for clinical use.

This is a bright spot for the nation’s clinical pathology laboratories. That’s because many genetic tests and molecular assays deliver significant clinical value to the physician and his or her patient—while generating ample reimbursement for the medical laboratory that performs these tests.


Pathology Laboratories Take Steps to Bring Web 2.0 Functions into Digital Pathology

Enriched exchange of digital pathology images and clinical knowledge is the goal

Digital scanning and digital pathology systems represent a major transformational force in the field of anatomic pathology. Momentum in favor of wider adoption by pathologists and pathology laboratories continues to build, reinforced, in part, by an interesting new development, which one pathologist calls “Pathology 2.0.”

Pathology 2.0 describes how Web 2.0 functions can be integrated with digital imaging and digital pathology systems to improve the productivity and quality of pathology workflow. It was Keith Kaplan, M.D., Associate Professor of Pathology and Laboratory Medicine at the Mayo Clinic in Rochester, Minnesota, who first articulated the intersection of digital scanning and digital pathology systems with Web 2.0 functions as the core of Pathology 2.0, a term he coined.